GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bakhu Holdings Corp (OTCPK:BKUH) » Definitions » Risk Assessment

Bakhu Holdings (Bakhu Holdings) Risk Assessment


View and export this data going back to 2009. Start your Free Trial

What is Bakhu Holdings Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Bakhu Holdings is: No Data: Cannot be evaluated.

Competitive Comparison of Bakhu Holdings's Risk Assessment

For the Drug Manufacturers - Specialty & Generic subindustry, Bakhu Holdings's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bakhu Holdings's Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bakhu Holdings's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Bakhu Holdings's Risk Assessment falls into.


Bakhu Holdings  (OTCPK:BKUH) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Bakhu Holdings Risk Assessment Related Terms

Thank you for viewing the detailed overview of Bakhu Holdings's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Bakhu Holdings (Bakhu Holdings) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bakhu Holdings Corp (OTCPK:BKUH) » Definitions » Risk Assessment
Comparable Companies
ORGO PROC SIGA LFCR RGC ASRT CHHE EGRX ALIM EOLS ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
N/A
Address
One World Trade Center, Suite 130, Long Beach, CA, USA, 90831
Website
https://www.bakhuholdings.com
Bakhu Holdings Corp is a development stage company engaged in the production, manufacturing, and sale of cannabis and byproducts. The company also provides cannabis-related research, teaching and education for both medical and other purposes, and all medical uses and applications of cannabis, within the Territory.
Executives
Tom Vaknin director SPYROU KYPRIANOU 16, PYGROS / LIMMASOL G4 4529
Moshe Morgenstern director MENACHEM BEGIN 88, PETAH TIKVAH/CENTRAL DISTRICT L3 49504
Geoffrey Robert Dixon 10 percent owner 16 SHOBY LANE, GRIMSTON X0 LE14 3DD
Michael Richard Hawthorne officer: Deputy CEO 20 LARKSBOROUGH AVENUE, COUNTY DOWN X0 BT23 8SU
Garcia La Sienra Garcia Juan Carlos director, officer: CFO 3 SHANEWOOD CT, THE WOODLANDS TX 77382
Sagi Rami Rozen director HOUSE NUMBER 8, 8 AGIAS TRIADAS STREET (MOUTTAGIAKA), LIMASSOL G4 4527
Cell Science Holding, Ltd. 10 percent owner PANTELI KATELARI 18A, AGIOS IOANNIS, LIMASSOL G4 3012
Mentone, Ltd. 10 percent owner 3 COPLOW CRESCENT, SYSTON, LEICESTER X0 LE7 2JE
Inter-m Traders Fz, Lle 10 percent owner 18A PENTELI KATELARI, LIMASSOL G4 3021
Thomas K Emmitt director, officer: President, CEO and Secretary ONE WORLD TRADE CENTER, SUITE 130, LONG BEACH CA 90831
Aristotle Popolizio director 206 PASSAIC AVENUE, ROSELAND NJ 07068
Evripides Drakos director 139C GLOUCESTER TERRACE, LANCASTER GATE, LONDON X0 W2 6DX
Peter Whitton director 3 COPLOW CRESCENT, SYSTON LEICESTER X0 LE7 2JE
Oz Corp 10 percent owner 24328 VERMONT AVENUE, SUITE 300, HARBOR CITY CA 90710